Hospital
Las Cruces Medical Center LLC
Las Cruces Medical Center LLC was paid $86.66M by Medicaid between Jan 2018 and Dec 2024, across 407 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 16% of everything it billed.
33Billing provider infoLAS CRUCES MEDICAL CENTER LLC
LAS CRUCES, NM 88011
LAS CRUCES, NM 88011
33aNPI1205882503assigned 05/26/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$86.66M
24GClaims1,891,109
24DCodes billed407
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Mexico
Rank by total paid#1 of 24
Median peer was paid$20.13M
This provider vs. median4.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 320,008 | $13.80M | |
| 2019 | 235,614 | $10.93M | |
| 2020 | 187,670 | $8.99M | |
| 2021 | 238,103 | $11.10M | |
| 2022 | 290,141 | $13.71M | |
| 2023 | 321,339 | $14.67M | |
| 2024incomplete | 298,234 | $13.47M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 16% | 149,727 | 141,120 | $13.76M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 71,361 | 68,942 | $10.68M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 49,011 | 46,312 | $9.64M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.8% | 11,732 | 11,240 | $4.99M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.3% | 11,465 | 10,778 | $2.83M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 10,240 | 9,765 | $2.25M |
| 80053 | Comprehensive metabolic panel | 2.2% | 109,035 | 95,201 | $1.95M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 18,111 | 17,758 | $1.76M |
| 87430 | 2.0% | 82,620 | 80,574 | $1.73M | |
| 87400 | 1.7% | 63,595 | 53,865 | $1.47M | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.6% | 48,890 | 47,489 | $1.41M |
| 71045 | Radiologic examination, chest; single view | 1.6% | 22,113 | 20,592 | $1.36M |
395 more codes
| G0378 | Hospital observation service, per hour | 1.5% | 3,440 | $1.26M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 18,738 | $1.18M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.4% | 19,233 | $1.18M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 19,868 | $1.03M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 3,001 | $969K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 3,108 | $932K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 106,789 | $910K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,291 | $645K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 9,876 | $624K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,806 | $596K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 11,339 | $582K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,531 | $578K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 21,976 | $572K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,244 | $571K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,526 | $522K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 16,129 | $501K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,754 | $443K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 549 | $429K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 26,756 | $375K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,513 | $371K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,709 | $367K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 33,687 | $353K |
| 95811 | <1% | 510 | $351K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 9,900 | $349K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 9,880 | $347K |
| 59025 | Fetal non-stress test | <1% | 3,225 | $329K |
| 73562 | <1% | 3,867 | $328K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 37,384 | $320K |
| 87070 | <1% | 21,006 | $312K | |
| 73610 | <1% | 3,251 | $301K | |
| 80061 | Lipid panel | <1% | 21,754 | $292K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 9,462 | $281K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,337 | $272K |
| 86900 | <1% | 11,564 | $251K | |
| 76801 | <1% | 2,080 | $250K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 20,334 | $247K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 14,284 | $245K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,182 | $243K |
| 73630 | <1% | 3,562 | $241K | |
| 70496 | <1% | 924 | $240K | |
| 70498 | <1% | 944 | $238K | |
| 73030 | <1% | 2,966 | $237K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,152 | $231K |
| 74018 | <1% | 3,430 | $229K | |
| 73130 | <1% | 3,346 | $228K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 62,423 | $226K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 14,706 | $222K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,687 | $221K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 797 | $214K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 414 | $213K |
| 84703 | <1% | 21,739 | $207K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,986 | $200K |
| 70486 | <1% | 962 | $195K | |
| 93971 | <1% | 1,975 | $192K | |
| 72100 | <1% | 2,091 | $188K | |
| 84484 | <1% | 19,275 | $172K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,683 | $169K |
| 47562 | <1% | 63 | $168K | |
| 73110 | <1% | 2,292 | $159K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 473 | $157K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,266 | $157K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 444 | $154K |
| 93976 | <1% | 927 | $148K | |
| 83690 | <1% | 23,933 | $139K | |
| 86780 | <1% | 9,605 | $135K | |
| 76641 | <1% | 1,175 | $135K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 16,092 | $132K |
| 93017 | <1% | 768 | $131K | |
| 71250 | <1% | 867 | $124K | |
| 80074 | <1% | 2,829 | $124K | |
| 58661 | <1% | 40 | $121K | |
| 93970 | <1% | 853 | $120K | |
| 86850 | <1% | 9,903 | $118K | |
| 76775 | <1% | 1,046 | $117K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,900 | $113K |
| 81003 | <1% | 49,719 | $113K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,201 | $113K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 250 | $108K |
| 70491 | <1% | 290 | $106K | |
| 84702 | <1% | 6,700 | $106K | |
| 85027 | <1% | 17,361 | $104K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 20,365 | $103K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,704 | $93K |
| 97161 | <1% | 2,897 | $91K | |
| 73140 | <1% | 1,289 | $90K | |
| 86901 | <1% | 11,546 | $89K | |
| 87186 | <1% | 6,327 | $85K | |
| 12001 | <1% | 840 | $84K | |
| 83880 | <1% | 3,534 | $80K | |
| 87088 | <1% | 5,232 | $78K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,175 | $78K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,603 | $77K |
| 87040 | <1% | 6,381 | $77K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,424 | $77K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,227 | $76K |
| 73080 | <1% | 1,164 | $75K | |
| 95806 | <1% | 393 | $74K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 695 | $74K |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 4,348 | $73K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,476 | $71K |
| 72040 | <1% | 844 | $71K | |
| 88312 | <1% | 734 | $68K | |
| 76536 | <1% | 656 | $67K | |
| 72131 | <1% | 322 | $65K | |
| 73700 | <1% | 301 | $64K | |
| 87420 | <1% | 3,573 | $63K | |
| 84439 | <1% | 7,664 | $62K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,423 | $61K |
| 83735 | <1% | 12,447 | $59K | |
| 82962 | <1% | 14,167 | $58K | |
| 85610 | <1% | 13,959 | $57K | |
| 73090 | <1% | 848 | $57K | |
| 86803 | <1% | 4,568 | $56K | |
| 73590 | <1% | 851 | $55K | |
| 29125 | <1% | 383 | $52K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 433 | $51K |
| 82607 | <1% | 4,147 | $51K | |
| 82728 | <1% | 4,433 | $50K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 908 | $50K |
| 83605 | <1% | 6,259 | $49K | |
| 87653 | <1% | 1,480 | $48K | |
| 76770 | <1% | 524 | $48K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 123 | $48K |
| 86696 | <1% | 2,359 | $47K | |
| 81001 | <1% | 16,670 | $47K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,945 | $47K |
| C1762 | Connective tissue, human (includes fascia lata) | <1% | 52 | $46K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,601 | $45K |
| 93458 | <1% | 31 | $44K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,701 | $44K |
| 86762 | <1% | 3,697 | $42K | |
| 73502 | <1% | 826 | $41K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 287 | $41K |
| J2704 | Injection, propofol, 10 mg | <1% | 8,956 | $40K |
| 84403 | <1% | 1,682 | $40K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 703 | $39K |
| 86787 | <1% | 3,540 | $38K | |
| 83013 | <1% | 635 | $37K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,416 | $37K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,087 | $36K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,378 | $36K |
| 90715 | <1% | 2,394 | $36K | |
| 10060 | <1% | 407 | $35K | |
| 82077 | <1% | 2,752 | $35K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 99 | $34K |
| 87340 | <1% | 4,085 | $34K | |
| 86695 | <1% | 2,342 | $34K | |
| 82105 | <1% | 1,991 | $32K | |
| 31720 | <1% | 250 | $32K | |
| 85379 | <1% | 3,840 | $32K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 739 | $32K |
| 83001 | <1% | 1,768 | $31K | |
| H0049 | Alcohol and/or drug screening | <1% | 1,488 | $31K |
| 85730 | <1% | 6,108 | $31K | |
| 97165 | <1% | 1,117 | $30K | |
| 12002 | <1% | 282 | $30K | |
| 73221 | <1% | 102 | $30K | |
| 84146 | <1% | 1,588 | $29K | |
| 84402 | <1% | 1,220 | $29K | |
| 84481 | <1% | 1,921 | $29K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 2,254 | $29K |
| 84145 | <1% | 603 | $28K | |
| 86038 | <1% | 2,273 | $27K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 207 | $27K |
| 76870 | <1% | 230 | $26K | |
| 82746 | <1% | 2,208 | $26K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,694 | $26K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 254 | $26K |
| 86140 | <1% | 5,023 | $26K | |
| 12011 | <1% | 250 | $25K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 53 | $25K |
| 94770 | <1% | 210 | $24K | |
| 82570 | <1% | 5,700 | $24K | |
| 83002 | <1% | 1,347 | $24K | |
| 77080 | <1% | 305 | $23K | |
| 94727 | <1% | 248 | $23K | |
| 83540 | <1% | 3,417 | $23K | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 6,137 | $23K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 141 | $23K |
| 82803 | <1% | 720 | $23K | |
| 96376 | <1% | 2,008 | $22K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 49 | $21K |
| 88307 | <1% | 108 | $21K | |
| 72072 | <1% | 205 | $20K | |
| 82670 | <1% | 729 | $20K | |
| 97116 | <1% | 1,533 | $20K | |
| 84112 | <1% | 529 | $20K | |
| 87077 | <1% | 1,305 | $19K | |
| C1769 | Guide wire | <1% | 804 | $19K |
| 94060 | <1% | 202 | $19K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,644 | $19K |
| 80143 | <1% | 1,196 | $19K | |
| 99152 | <1% | 798 | $19K | |
| 80179 | <1% | 1,180 | $18K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,358 | $18K |
| 72141 | <1% | 64 | $17K | |
| 84153 | <1% | 1,082 | $16K | |
| 76857 | <1% | 204 | $16K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 251 | $16K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 36 | $15K |
| 83525 | <1% | 1,356 | $15K | |
| 73560 | <1% | 293 | $15K | |
| 83550 | <1% | 2,087 | $15K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 40 | $15K |
| 84156 | <1% | 3,455 | $15K | |
| 82043 | <1% | 2,844 | $14K | |
| 82950 | <1% | 3,152 | $14K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,888 | $14K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 194 | $14K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,600 | $14K |
| 85652 | <1% | 5,576 | $14K | |
| 76642 | <1% | 173 | $14K | |
| 82247 | <1% | 2,500 | $13K | |
| 82248 | <1% | 2,616 | $13K | |
| 84550 | <1% | 2,695 | $13K | |
| 71100 | <1% | 219 | $13K | |
| 36591 | <1% | 374 | $12K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,828 | $12K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 55 | $12K |
| 80050 | General health panel | <1% | 789 | $12K |
| 87081 | <1% | 1,679 | $12K | |
| 84480 | <1% | 998 | $12K | |
| 82550 | <1% | 2,285 | $11K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,060 | $11K |
| 82627 | <1% | 482 | $11K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,494 | $11K |
| 87210 | <1% | 1,583 | $11K | |
| 0002A | <1% | 218 | $10K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 29 | $10K |
| 95816 | <1% | 72 | $10K | |
| 72170 | <1% | 123 | $10K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 513 | $10K |
| 86235 | <1% | 262 | $10K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,771 | $9K |
| 83021 | <1% | 638 | $9K | |
| 83615 | <1% | 1,754 | $9K | |
| 82150 | <1% | 1,815 | $9K | |
| 73660 | <1% | 140 | $9K | |
| 87205 | <1% | 2,421 | $9K | |
| 87428 | <1% | 162 | $9K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 80 | $9K |
| 84163 | <1% | 568 | $9K | |
| 73552 | <1% | 155 | $9K | |
| 94729 | <1% | 249 | $8K | |
| 84100 | <1% | 2,543 | $8K | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 72 | $8K |
| 73060 | <1% | 138 | $8K | |
| 74021 | <1% | 105 | $8K | |
| 87660 | <1% | 329 | $8K | |
| 87480 | <1% | 329 | $8K | |
| 87510 | <1% | 329 | $8K | |
| 72110 | <1% | 77 | $8K | |
| 36430 | <1% | 34 | $7K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 190 | $7K |
| 85007 | <1% | 2,432 | $7K | |
| 86431 | <1% | 1,427 | $7K | |
| 80076 | <1% | 886 | $7K | |
| 97162 | <1% | 211 | $7K | |
| 87899 | <1% | 201 | $7K | |
| 82553 | <1% | 888 | $7K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,637 | $6K |
| C1781 | Mesh (implantable) | <1% | 26 | $6K |
| 86141 | <1% | 544 | $6K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 921 | $6K |
| 86376 | <1% | 410 | $5K | |
| 87522 | Neg quan hep c or qual rna | <1% | 85 | $5K |
| 73120 | <1% | 43 | $5K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 83 | $5K |
| D2929 | <1% | 25 | $5K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,022 | $5K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 205 | $4K |
| 76882 | <1% | 43 | $4K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 104 | $4K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,090 | $4K |
| 82565 | <1% | 1,080 | $4K | |
| 86160 | <1% | 345 | $4K | |
| 82784 | <1% | 466 | $4K | |
| 83970 | <1% | 126 | $4K | |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 82 | $4K |
| 87902 | <1% | 14 | $4K | |
| 84425 | <1% | 227 | $4K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 280 | $4K |
| 82626 | <1% | 151 | $4K | |
| 92523 | <1% | 48 | $4K | |
| 92610 | <1% | 66 | $4K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 581 | $4K |
| 86225 | <1% | 249 | $3K | |
| 82947 | <1% | 868 | $3K | |
| 70460 | <1% | 13 | $3K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 373 | $3K |
| 83655 | <1% | 291 | $3K | |
| 86003 | <1% | 38 | $3K | |
| 87209 | <1% | 141 | $3K | |
| 87045 | <1% | 305 | $3K | |
| 86200 | <1% | 276 | $3K | |
| 0240U | <1% | 146 | $3K | |
| 74022 | <1% | 39 | $3K | |
| 88342 | <1% | 44 | $3K | |
| 73200 | <1% | 13 | $3K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 466 | $3K |
| 86480 | <1% | 49 | $3K | |
| 85018 | <1% | 1,279 | $3K | |
| 83498 | <1% | 100 | $3K | |
| 97035 | <1% | 169 | $3K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 648 | $2K |
| 51702 | <1% | 38 | $2K | |
| 85014 | <1% | 1,089 | $2K | |
| 82140 | <1% | 246 | $2K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 321 | $2K |
| 36592 | <1% | 48 | $2K | |
| 86308 | <1% | 337 | $2K | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 361 | $2K |
| 93925 | <1% | 26 | $2K | |
| 73620 | <1% | 27 | $2K | |
| 86364 | <1% | 176 | $2K | |
| 86328 | <1% | 140 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 589 | $2K |
| 96367 | <1% | 123 | $2K | |
| 86800 | <1% | 122 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 114 | $2K |
| 87493 | <1% | 50 | $2K | |
| 87177 | <1% | 141 | $2K | |
| 86592 | <1% | 342 | $2K | |
| 85041 | <1% | 628 | $2K | |
| 82272 | <1% | 397 | $1K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 287 | $1K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 989 | $1K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 384 | $1K |
| 84132 | <1% | 362 | $1K | |
| 87075 | <1% | 128 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 297 | $1K |
| 84450 | <1% | 222 | $1K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 115 | $1K |
| 84460 | <1% | 205 | $1K | |
| 74240 | <1% | 12 | $947.55 | |
| 36600 | <1% | 99 | $920.61 | |
| 86255 | <1% | 42 | $918.56 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 308 | $908.98 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 319 | $897.19 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 207 | $835.87 |
| 72081 | <1% | 12 | $827.20 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 176 | $810.01 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 27 | $789.71 |
| 80164 | <1% | 72 | $708.52 | |
| 88304 | <1% | 26 | $689.07 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 250 | $688.77 |
| 84436 | <1% | 93 | $681.98 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 151 | $680.43 |
| 86706 | <1% | 42 | $664.76 | |
| 82951 | <1% | 40 | $640.68 | |
| 83516 | <1% | 64 | $635.50 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 106 | $579.09 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 206 | $554.59 |
| 83721 | <1% | 62 | $521.07 | |
| 86665 | <1% | 12 | $469.87 | |
| 82525 | <1% | 40 | $465.09 | |
| 96368 | <1% | 85 | $452.81 | |
| 85045 | <1% | 72 | $427.14 | |
| 84630 | <1% | 53 | $418.01 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 137 | $387.89 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 121 | $350.06 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 114 | $322.66 |
| G0008 | Administration of influenza virus vaccine | <1% | 18 | $312.20 |
| 84590 | <1% | 43 | $306.42 | |
| 82009 | <1% | 71 | $264.01 | |
| 82533 | <1% | 15 | $263.50 | |
| 84520 | <1% | 126 | $260.32 | |
| 83520 | <1% | 12 | $213.75 | |
| 90686 | <1% | 17 | $212.02 | |
| 86704 | <1% | 13 | $211.80 | |
| 82977 | <1% | 28 | $194.58 | |
| 85049 | <1% | 67 | $193.15 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 802 | $185.60 |
| 82330 | <1% | 16 | $178.49 | |
| 87338 | <1% | 12 | $168.94 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 13 | $160.86 |
| 82390 | <1% | 14 | $145.91 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 18 | $134.35 |
| 80069 | <1% | 13 | $94.98 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 15 | $76.12 |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 115 | $75.82 |
| 84295 | <1% | 14 | $59.48 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 32 | $55.64 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 13 | $48.17 |
| G2011 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention, 5-14 minutes | <1% | 39 | $47.37 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 23 | $19.19 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 65 | $6.12 |
| 91300 | <1% | 217 | $0.79 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 131 | $0.00 |
| G8986 | Carrying, moving & handling objects functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 14 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 106 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 442 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 141 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 364 | $0.00 |
| 99408 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.